Mereo BioPharma Group plc PDMR Notification (8185B)
12 Octobre 2020 - 2:44PM
UK Regulatory
TIDMMPH
RNS Number : 8185B
Mereo BioPharma Group plc
12 October 2020
Mereo BioPharma Group plc
PDMR Notification
London and Redwood City, Calif ., October 12, 2020 - Mereo
BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or "the
Company", a clinical-stage biopharmaceutical company focused on
oncology and rare diseases, received notification that on October
09, 2020, Charles Sermon, General Counsel at Mereo, purchased
18,405 American Depositary Shares (ADSs) at a price of USD 2.41 per
ADS.
The below announcement and notification is made in accordance
with the EU Market Abuse Regulation. The form required under the EU
Market Abuse Regulation follows.
1 Details of the person discharging managerial responsibilities
a) Name Charles Sermon
------------------------ --------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
a) Position/status General Counsel
------------------------ --------------------------------------------------
b) Initial notification/ Initial notification
Amendment
------------------------ --------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name Mereo BioPharma Group plc
------------------------ --------------------------------------------------
b) LEI 213800U8JQHIJOS5AS09
------------------------ --------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----------------------------------------------------------------------------
a) Description of AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING
the financial 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES
instrument, type OF GBP0.003 EACH
of instrument
and identification
code
------------------------ --------------------------------------------------
b) Nature of the PURCHASE
transaction
------------------------ --------------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) USD 2.41 18,405
----------
------------------------ --------------------------------------------------
d) Aggregated information:
volume, Price
------------------------ --------------------------------------------------
e) Date of the transaction 2020-10-09
------------------------ --------------------------------------------------
f) Place of the XNMS (Nasdaq Global Market)
transaction
------------------------ --------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBDBDGBSBDGGD
(END) Dow Jones Newswires
October 12, 2020 08:44 ET (12:44 GMT)
Mereo Biopharma (LSE:MPH)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Mereo Biopharma (LSE:MPH)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024